Core Viewpoint - The innovative drug market is not over yet, with numerous catalysts and potential growth opportunities ahead [1][2] Group 1: Market Catalysts - Upcoming academic conferences such as WCLC, ESMO, ASH, and ERS will provide platforms for companies to showcase their latest pipeline data [1] - Continuous disclosure of high-quality data will lead to an increase in pipeline valuations, driving market capitalization and valuations upward [1] Group 2: Market Dynamics - The pharmaceutical sector, particularly innovative drugs, has seen significant gains since the beginning of the year, with rapid rotation within the industry [1] - Short-term fluctuations in core innovative drug targets are primarily influenced by capital flow, with recent adjustments reaching a relative extreme, potentially indicating a bottom or a good entry point for accumulation [1] Group 3: Investment Opportunities - Focus on undervalued segments with growth potential, such as hepatitis B interferon treatment and digital robotics, which are at a critical stage of development [2] - Chain pharmacies are at historical lows and may present future investment opportunities as performance improves and market styles shift [2] - The pharmaceutical industry is characterized by essential demand and long-term growth potential, making it suitable for systematic investment [2]

Core Viewpoint - The company focuses on digital empowerment in its main business areas, advancing a national strategy for high-quality development, and emphasizes the integration of AI and blockchain technologies to enhance its service offerings [1][2][3] Group 1: Business Strategy and Development - The company aims to achieve a revenue of 555 million yuan in 2024, reflecting a 3.14% increase year-on-year, indicating stable operational growth [1] - The company is committed to AI research and application, establishing multiple innovation platforms and collaborating with institutions like Nanyang Technological University to enhance technological development [1][2] - The company has expanded its market presence to over 20 provinces, serving nearly 500 million people, with a 29.90% increase in revenue from external markets [3] Group 2: Product Innovation and R&D - The company has developed a range of new products addressing digital transformation challenges, including intelligent fund supervision and digital robots, enhancing its product competitiveness [2][5] - The company has invested 356.67 million yuan in R&D from 2022 to 2024, with 533 intellectual property rights, including 53 patents, showcasing its commitment to innovation [5][6] Group 3: Shareholder Returns and Governance - The company has distributed a total of 132 million yuan in cash dividends since its listing, with a proposed dividend of 0.65 yuan per share for 2024, representing 40.58% of its net profit [6] - The company has held multiple board meetings and training sessions to enhance governance and compliance, ensuring effective decision-making and adherence to regulations [7][9] Group 4: Internal Control and Communication - The company emphasizes the importance of a robust internal control system to mitigate risks and enhance operational efficiency [8] - The company maintains transparent communication with investors through various channels, ensuring they are well-informed about the company's performance and strategic direction [9]

将投中网设为"星标⭐"，第一时间收获最新推送 规模引入工业AI专用算力，配合柔性生产和软硬件升级，将是一次非常大的变革性机会。 整理丨 鲁智高 来源丨 投中网 时代的潮流，将科技投资推上前台。抓住其中的投资机会，关键在于洞察科技发展、产业发展的底层规律。 在华业天成创始合伙人孙业林看来，从工业革命到科技革命，生产力工具一直持续产生重大进化，从而带动产业生态产生了几次关键跃迁， " 未来，最 重要的生产力工具是机器人，一种是带身体的实体机器人，一种是没有身体的数字机器人。 " 与此同时，对于全球最大的工业制造国 —— 中国，孙业林认为这一波智能科技，将使工业连接从有线逐渐升级为 5G 等无线连接方式，规模引入工业 AI 专用算力，配合柔性生产和软硬件升级，将是一次非常大的变革性机会。 2025 年 4 月 16-18 日，由投中信息、投中网共同主办的第 19 届中国投资年会 · 年度峰会在中关村国际创新中心隆重召开。在活动现场，孙业林发 表了题为 " 智能科技投资策略探讨 " 的主题演讲。 以下为嘉宾现场演讲实录，由投中网整理： 各位嘉宾上午好，非常感谢投中的邀请，来做一个关于智能科技投资的分享。 锁定未来行业 ...